What is King Pharmaceuticals's treasury stock?

King Pharmaceuticals (KG) reported treasury stock of $51.95M in Q1 2026.

What does treasury stock mean?

Shares repurchased by the company and held in treasury, reducing equity. Recorded at cost and presented as a negative equity component.

King Pharmaceuticals KG Treasury Stock

Treasury Stock at other companies

Arch Capital GroupACGL

$7.22B+53.2%

Everest GroupEG

$5.24B+21.5%

Skyward Specialty Insurance Group, Inc.SKWD

$8.67M—

Selective Insurance GroupSIGI

$778.45M+15.1%

Reinsurance Group of AmericaRGA

$2.06B+9.0%

Verisk Analytics, Inc.VRSK

$12.13B+18.1%

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-71.3%

Enterprise value$184.93M-52.3%

P/E1.2×—

P/S1.6×-27.7×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:TreasuryStockCommonValue.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's treasury stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's treasury stock?: King Pharmaceuticals (KG) reported treasury stock of $51.95M in Q1 2026.
What does treasury stock mean?: Shares repurchased by the company and held in treasury, reducing equity. Recorded at cost and presented as a negative equity component.